Analysts’ Viewpoint on Critical Limb Ischemia Treatment Market Scenario
Critical limb ischemia is an advanced stage of peripheral arterial disease. Rise in prevalence of critical limb ischemia has increased the need of constantly improving endovascular techniques, such as arterial revascularization, with non-invasive treatment approach. Growth in prevalence of critical limb ischemia, rich product pipeline, and adoption of promising therapeutic strategies such as optimal revascularization are expected to augment the global critical limb ischemia treatment market during the forecast period. Key players are focusing on optimizing various critical limb ischemia-associated cardiovascular risk factors to improve the outcomes of recently developed treatments. Hence, ongoing research in gene and cell-based therapies is anticipated to propel the global market. High economic burden of critical limb ischemia in developing countries is anticipated to underpin demand for treatments in these regions.
Critical limb ischemia (CLI) is a severe peripheral arterial disease (PAD), wherein chronic inflammation associated with atherosclerosis (progressive thickening of artery lining) causes reduced blood flow to the extremities (legs, feet, and hands), leading to severe pain and ulcers or sore. Major risk factors for critical limb ischemia are age (people aged 60 or over are at high risk of developing this diseased condition), obesity, diabetes, high cholesterol level, smoking, sedentary lifestyle, and high blood pressure. Critical limb ischemia is associated with symptoms such as ischemic rest pain, gangrene, or tissue loss. Rise in prevalence of critical limb ischemia is anticipated to increase the demand for therapeutics, thereby driving the global chronic limb ischemia treatment market. Furthermore, growth in health care expenditure and rise in number of clinical trials are likely to propel the global chronic limb ischemia treatment market. Increase in patient population with critical limb ischemia, growth of the pharmaceutical industry, improvement in health care infrastructure, and surge in number of clinical trials are also projected to be the key drivers of the global market.
The COVID-19 pandemic has had a negative impact on the global critical limb ischemia treatment market. This is despite the fact that a large percentage of population in some regions has been vaccinated with all the required jabs. Governments of affected countries deferred non-essential surgeries and patient visits during the breakout year of the pandemic. This led to a decline in overall critical limb ischemia diagnosis and treatments in hospitals and clinics. Limited understanding of the epidemiology and etiology of the disease is a key factor that has constrained the development of effective therapeutic options. Thus, leading players in the critical limb ischemia treatment market reported a decline in revenue due to the pandemic. However, the market has been recovering from COVID-19 due to the easing of restrictions by governments across the globe.
In terms of treatment, the devices segment is projected to account for dominant share of the global critical limb ischemia treatment market during the forecast period. Dilation devices and stents provide dilation effectively and protect the artery wall. These are the frequently used devices in the treatment for critical limb ischemia. Dilation devices and stents also offer low complication rates and high technical success, leading to a better quality of life for patients. These advantages are projected to drive the devices segment during the forecast period. The segment's dominance can also be ascribed to the increase in FDA approval and patient preference for revascularization as the first line of treatment. Recently, optimized balloon angioplasty study of the Tack Endovascular System in Below the Knee Arteries (TOBA II BTK) has shown positive results in clinical trials.
The devices segment has been bifurcated into embolic protection devices and peripheral dilatation systems. The peripheral dilatation systems sub-segment is projected to account for major share of the devices segment during the forecast period. This can be ascribed to the increase in usage of balloon dilators and CLI vascular surgery. Leading players in the critical limb ischemia treatment market are focusing on the development and launch of technologically advanced peripheral dilatation devices. In June 2022, Cordis, a global leader in cardiovascular technologies, announced the human use of the Radianz Radial Peripheral System. The Radianz Radial Peripheral System solution includes BRITE TIP RADIANZTM Guiding Sheath used to optimize lower extremity lesion access, the SABERX RADIANZTM PTA Catheter to facilitate treatment, and the S.M.A.R.T. RADIANZTM Vascular Stent System to help maintain patency for lasting favorable outcomes.
The antiplatelet drugs sub-segment accounted for leading share of the medications segment in 2021. The sub-segment is projected to lose market share from 2022 to 2031. The antiplatelet drugs sub-segment is anticipated to grow at the fastest CAGR during the forecast period. Antiplatelet drugs are widely used in the treatment of critical limb ischemia and are easily available in retail stores. Additionally, major pharmaceutical manufacturers are focusing on the development of new antiplatelet drugs for the treatment of critical limb ischemia. This is likely to propel the critical limb ischemia treatment market size during the forecast period.
North America is projected to dominate the global critical limb ischemia treatment market in the next few years. The market in the region is expected to grow at a moderate CAGR during the forecast period. This can be ascribed to the increase in government initiatives and awareness about CLI and other risk-associated disorders, rise in healthcare expenditure, surge in disposable income, and the availability of technologically advanced devices in the region. According to a recent study, around 2 million to 3 million people suffer from critical limb ischemia in the U.S.
The market in Asia Pacific is anticipated to grow at a high CAGR from 2022 to 2031. The critical limb ischemia treatment market in the region is driven by the rise in prevalence of CLI in countries such as India and China, increase in geriatric population, surge in health care spending, and government initiatives. Large population, unmet medical needs, and rise in patient awareness are anticipated to propel the market in the region. Economic growth in emerging economies such as India and China is enhancing the purchasing capabilities of consumers due to the increase in disposable income. This is likely to augment the market in these countries in the near future.
The critical limb ischemia treatment market report includes vital information about the leading players in the critical limb ischemia treatment market. Companies are focusing on strategies such as new product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the market. Boston Scientific Corporation, Cesca Therapeutics, Inc., Abbott Laboratories, Pluristem Therapeutics, Inc., Rexgenero Ltd., LimFlow SA, Micro Medical Solutions, and Cardiovascular Systems, Inc. are the prominent players operating in the global market.
Each of these players has been profiled in the critical limb ischemia treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 1.61 Bn |
|
Market Forecast Value in 2031 |
More than US$ 3.49 Bn |
|
Compound Annual Growth Rate (CAGR) |
8.09% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global critical limb ischemia treatment market was valued at US$ 1.61 Bn in 2021
The global market is projected to reach more than US$ 3.49 Bn by 2031
The global critical limb ischemia treatment market is anticipated to grow at a CAGR of 8.09% from 2022 to 2031
Increase in incidence of critical limb ischemia across the globe and rise in patient preference for minimally invasive therapies
North America is expected to account for major share of the global critical limb ischemia treatment market during the forecast period
Boston Scientific Corporation, Cesca Therapeutics, Inc., Abbott Laboratories, Pluristem Therapeutics, Inc., Rexgenero Ltd., LimFlow SA, Micro Medical Solutions, and Cardiovascular Systems, Inc.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Product Overview
4.2. Market Dynamics
4.2.1. Drivers and Restraints Snapshot Analysis
4.2.2. Drivers
4.2.3. Restraints
4.2.4. Opportunity
4.3. Global Critical Limb Ischemia Treatment Market Revenue Projection (US$ Mn), 2017–2027
4.4. Global Critical Limb Ischemia Treatment Market Outlook
5. Market Outlook
5.1. Pipeline Analysis
5.2. Key Industry Events
5.3. Regulatory Scenario for Device
5.4. Prevalence of Critical Limb Ischemia Globally/Region
5.5. Major Research Institutes Involved
5.6. Technological Advancement
6. Global Critical Limb Ischemia Treatment Market Analysis, by Treatment
6.1. Key Findings
6.2. Introduction
6.3. Global Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
6.4. Global Critical Limb Ischemia Treatment Market Forecast, by Treatment
6.4.1. Devices
6.4.2. Medication
6.5. Global Critical Limb Ischemia Treatment Market Analysis, by Treatment
7. Global Critical Limb Ischemia Treatment Market Analysis, by Region
7.1. Global Critical Limb Ischemia Treatment Market Scenario, by Country
7.2. Global Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Region
7.3. Global Critical Limb Ischemia Treatment Market Forecast, by Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
8. North America Critical Limb Ischemia Treatment Market Analysis
8.1. Key Findings
8.2. North America Critical Limb Ischemia Treatment Market Overview
8.3. North America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country
8.4. North America Critical Limb Ischemia Treatment Market Forecast, by Country
8.4.1. U.S.
8.4.2. Canada
8.5. North America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
8.6. North America Critical Limb Ischemia Treatment Market Forecast, by Treatment
8.6.1. Devices
8.6.2. Medication
9. Europe Critical Limb Ischemia Treatment Market Analysis
9.1. Key Findings
9.2. Europe Critical Limb Ischemia Treatment Market Overview
9.3. Europe Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
9.4. Europe Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
9.4.1. Germany
9.4.2. France
9.4.3. U.K.
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Europe Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
9.6. Europe Critical Limb Ischemia Treatment Market Forecast, by Treatment
9.6.1. Devices
9.6.2. Medication
10. Asia Pacific Critical Limb Ischemia Treatment Market Analysis
10.1. Key Findings
10.2. Asia Pacific Critical Limb Ischemia Treatment Market Overview
10.3. Asia Pacific Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
10.4. Asia Pacific Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Australia & New Zealand
10.4.5. Rest of Asia Pacific
10.5. Asia Pacific Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
10.6. Asia Pacific Critical Limb Ischemia Treatment Market Forecast, by Treatment
10.6.1. Devices
10.6.2. Medication
11. Latin America Critical Limb Ischemia Treatment Market Analysis
11.1. Key Findings
11.2. Latin America Critical Limb Ischemia Treatment Market Overview
11.3. Latin America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.4. Latin America Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Latin America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
11.6. Latin America Critical Limb Ischemia Treatment Market Forecast, by Treatment
11.6.1. Devices
11.6.2. Medication
12. Middle East & Africa Critical Limb Ischemia Treatment Market Analysis
12.1. Key Findings
12.2. Middle East & Africa Critical Limb Ischemia Treatment Market Overview
12.3. Middle East & Africa Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.4. Middle East & Africa Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of Middle East & Africa
12.5. Middle East & Africa Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
12.6. Middle East & Africa Critical Limb Ischemia Treatment Market Forecast, by Treatment
12.6.1. Devices
12.6.2. Medication
13. Competition Landscape
13.1. Competition Matrix
13.2. Company Profiles
13.2.1. Medtronic plc
13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.1.2. Product Portfolio
13.2.1.3. SWOT Analysis
13.2.1.4. Strategic Overview
13.2.2. Boston Scientific Corporation
13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.2.2. Product Portfolio
13.2.2.3. SWOT Analysis
13.2.2.4. Strategic Overview
13.2.3. Cesca Therapeutics, Inc.
13.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.3.2. Product Portfolio
13.2.3.3. SWOT Analysis
13.2.3.4. Strategic Overview
13.2.4. Abbott Laboratories
13.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.4.2. Product Portfolio
13.2.4.3. SWOT Analysis
13.2.4.4. Strategic Overview
13.2.5. Pluristem Therapeutics, Inc.
13.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.5.2. Product Portfolio
13.2.5.3. SWOT Analysis
13.2.5.4. Strategic Overview
13.2.6. Rexgenero Ltd.
13.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.6.2. Product Portfolio
13.2.6.3. SWOT Analysis
13.2.6.4. Strategic Overview
13.2.7. LimFlow SA
13.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.7.2. Product Portfolio
13.2.7.3. SWOT Analysis
13.2.7.4. Strategic Overview
13.2.8. Micro Medical Solutions
13.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.8.2. Product Portfolio
13.2.8.3. SWOT Analysis
13.2.8.4. Strategic Overview
13.2.9. Cardiovascular Systems, Inc.
13.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.9.2. Product Portfolio
13.2.9.3. SWOT Analysis
13.2.9.4. Strategic Overview
List of Tables
Table 01: Pipeline Analysis
Table 02: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031
Table 03: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031
Table 04: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031
Table 05: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031
Table 06: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Region, 2022–2031
Table 07: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country, 2022–2031
Table 08: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031
Table 09: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022–2031
Table 10: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System, 2022–2031
Table 11: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022–2031
Table 12: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2022–2031
Table 13: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031
Table 14: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022–2031
Table 15: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System, 2022–2031
Table 16: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022–2031
Table 17: Asia Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2022–2031
Table 18: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031
Table 19: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022–2031
Table 20: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System, 2022–2031
Table 21: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022–2031
Table 22: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2022–2031
Table 23: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031
Table 24: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022–2031
Table 25: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System, 2022–2031
Table 26: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022–2031
Table 27: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2022–2031
Table 28: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022–2031
Table 29: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022–2031
Table 30: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System,
Table 31: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022–2031
Table 32: Medtronic plc, Business Overview
Table 33: Boston Scientific Corporation Product Offerings
Table 34: Cesca Therapeutics Inc., Products & Services Offered
Table 35: Abbott Laboratories, Business Overview
Table 36: Pluristem Therapeutics Inc., Products & Services Offered
Table 37: Rexgenero Ltd, Products & Services Offered
Table 38: LimFlow SA, Products & Services Offered
Table 39: Micro Medical Solutions, Products & Services Offered
Table 40: Cardiovascular Systems, Inc., Products & Services Offered
List of Figures
Figure 01: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) and Distribution, by Region, 2021 and 2031
Figure 02: Global Critical Limb Ischemia Treatment Market Revenue Projection (US$ Mn), 2022–2031
Figure 03: Global Critical Limb Ischemia Treatment Market Value Share, by Treatment, 2021
Figure 04: Global Critical Limb Ischemia Treatment Market Value Share, by Region, 2021
Figure 05: U.S. FDA Medical Devices Approval Criteria
Figure 06: Classification of Medical Devices
Figure 07: European Approval for Medical Devices - Regulatory Pathway (Class IIb Devices only)
Figure 08: Regulatory Approval Process - U.S.
Figure 09: Regulatory Approval Process - Europe
Figure 10: Regulatory Approval Process - Japan
Figure 11: Prevalence of Critical Limb Ischemia Globally/Region
Figure 12: Global Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
Figure 13: Global Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 14: Global Critical Limb Ischemia Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Devices, 2022–2031
Figure 15: Global Critical Limb Ischemia Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Medication, 2022–2031
Figure 16: Global Critical Limb Ischemia Treatment Market Value Share, by Region, 2021 and 2031
Figure 17: Global Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Region, 2022–2031
Figure 18: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2031
Figure 19: North America Critical Limb Ischemia Treatment Market Value Share Analysis, by Country, 2021 and 2031
Figure 20: North America Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Country, 2022–2031
Figure 21: North America Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
Figure 22: North America Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 23: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2031
Figure 24: Europe Critical Limb Ischemia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 25: Europe Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 26: Europe Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
Figure 27: Europe Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 28: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2031
Figure 29: Asia Pacific Critical Limb Ischemia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 30: Asia Pacific Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 31: Asia Pacific Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
Figure 32: Asia Pacific Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 33: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2031
Figure 34: Latin America Critical Limb Ischemia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 35: Latin America Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 36: Latin America Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
Figure 37: Latin America Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 38: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2031
Figure 39: Middle East & Africa Critical Limb Ischemia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 40: Middle East & Africa Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 41: Middle East & Africa Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
Figure 42: Middle East & Africa Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 43: Medtronic plc, Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2021
Figure 44: Medtronic plc, Breakdown of Net Sales (%), by Geography, 2021
Figure 45: Medtronic plc, Breakdown of Net Sales (%), by Business Segment, 2021
Figure 46: Medtronic plc, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2021
Figure 47: Boston Scientific Corporation, Revenue (US$ Bn) and Y-o-Y Growth (%), 2018–2021
Figure 48: Boston Scientific Corporation, Breakdown of Net Sales, by Region, 2021
Figure 49: Boston Scientific Corporation, Breakdown of Net Sales, by Business Segment, 2021
Figure 50: Cesca Therapeutics Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2018–2021
Figure 51: Cesca Therapeutics Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2021
Figure 52: Cesca Therapeutics Inc. Breakdown of Net Sales, by Region, 2021
Figure 53: Cesca Therapeutics Inc. Sales & Marketing Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2021
Figure 54: Abbott Laboratories, Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2021
Figure 55: Abbott Laboratories, R&D Intensity and Sales & Marketing Intensity (US$ Mn), 2018–2021
Figure 56: Abbott Laboratories, Breakdown of Net Sales, by Countries, 2021
Figure 57: Abbott Laboratories, Breakdown of Net Sales, by Business Segment, 2021
Figure 58: Cardiovascular Systems, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2021
Figure 59: Cardiovascular Systems, Inc. R&D Intensity and Sales & Marketing Intensity (US$ Mn), 2018–2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Critical Limb Ischemia Treatment Market
